Business Description
Vaxil Bio Ltd
NAICS : 325410
SIC : 3741
ISIN : CA92243L1076
Compare
Compare
Traded in other countries / regions
VXL.CanadaVXLLF.USA IPO Date
2016-03-14Description
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 33.3 | |||||
3-Year FCF Growth Rate | 40.7 | |||||
3-Year Book Growth Rate | -6.2 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 10.68 | |||||
9-Day RSI | 24.26 | |||||
14-Day RSI | 32.27 | |||||
3-1 Month Momentum % | -78.95 | |||||
6-1 Month Momentum % | -72.38 | |||||
12-1 Month Momentum % | -77.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.92 | |||||
Quick Ratio | 16.92 | |||||
Cash Ratio | 14.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | 52.43 | |||||
ROA % | 51.38 | |||||
ROIC % | -49.78 | |||||
ROC (Joel Greenblatt) % | -1432.26 | |||||
ROCE % | -24 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.97 | |||||
PE Ratio without NRI | 1 | |||||
PEG Ratio | 0.02 | |||||
PB Ratio | 0.57 | |||||
Price-to-Tangible-Book | 0.55 | |||||
EV-to-EBIT | -0.86 | |||||
EV-to-EBITDA | -0.86 | |||||
EV-to-FCF | -0.75 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.04 | |||||
Price-to-Graham-Number | 0.16 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 2.21 | |||||
Earnings Yield (Greenblatt) % | -116.28 | |||||
FCF Yield % | -35.56 |
GF Valueâ„¢
Vaxil Bio Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaxil Bio Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.02:1 Stock Split | 2025-05-15 | 0.26 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:VXLLF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Vaxil Bio Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers